
According to Fleischer, epicutaneous immunotherapy represents a “marathon, not a sprint,” with potential long-term benefits when started young.

According to Fleischer, epicutaneous immunotherapy represents a “marathon, not a sprint,” with potential long-term benefits when started young.

A large randomized trial found that a mid-pregnancy blood test paired with targeted interventions improved neonatal outcomes in low-risk pregnancies.

New data suggest climate-related heat exposure may influence early developmental trajectories, particularly among vulnerable children.

David Fleischer, MD, says phase 3 VITESSE results show the Viaskin peanut patch offers a safe, practical desensitization option for young children with peanut allergy.

Reactions from the pediatric health care community poured in following swift changes to the US childhood vaccine schedule by the CDC.

FDA approved caplacizumab for pediatric patients ≥12 years with acquired TTP, supported by retrospective data showing 80% remission.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from December 2025.

With the priority review, the Prescription Drug User Fee Act date is set for April 29, 2026, for potential approval in this younger indication.

Effective immediately, the updated US childhood vaccine schedule will reduce the number of recommended vaccines for all children to 11 diseases, down from 18.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

View our Q4 2025 recap of standout pediatric news from FDA regulatory updates, clinical trial results, and expert commentary.

Daniela Carvalho, MD, highlighted the role of pediatricians in guiding families through early hearing intervention and language development decisions.

The FDA approved narsoplimab-wuug as the first targeted treatment for transplant-associated thrombotic microangiopathy in adults and children.

Those with regular access to care who did not receive, or were late on 2- and 4-month recommended vaccines, were more likely to not have any MMR vaccine by 2 years of age.

Take a look back at the top 5 FDA approvals of 2025.

Check the top pediatric conferences of 2025.

These were the most-viewed articles on the Contemporary Pediatrics website published in 2025.

Check out the top 5 nutrition articles of 2025.

As we continue our Countdown to 2026, take a look back at our top video interviews and packages of 2025.

Check out the top 5 nutrition articles of 2025.

In this recap article, take a look back at some of our top stories in the infectious diseases space in 2025.

Check out the top 5 nutrition articles of 2025.

Check out the top 5 pharmacology articles of 2025.

Join us for a recap of some of our top dermatology puzzler cases from 2025.

Can you guess what condition Tiny Tim had?

Prenatal exposure to hot, humid conditions was associated with significantly reduced child growth, with effects far greater than heat alone.

Mimi C. Lee, MD, PhD, outlines why genomic sequencing remains a powerful but carefully targeted tool in pediatric medicine today, as advancements continue.

National EHR data show vitamin K nonreceipt among newborns nearly doubled from 2017 to 2024, raising concern for preventable bleeding risk.

“We started out 2025 with an environment that was rife with myths and disinformation," said Robert H. Hopkins, Jr., MD, in this year-end recap of 2025 and the pediatric vaccine landscape.

Approval of the expanded indication fullfilled all post-marketing requirements outlined in the original approval letter.